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Detecting cryptic clinically relevant structural
variation in exome-sequencing data increases
diagnostic yield for developmental disorders
Eugene J. Gardner,1,6 Alejandro Sifrim,2 Sarah J. Lindsay,1 Elena Prigmore,1 Diana Rajan,1
Petr Danecek,1 Giuseppe Gallone,1 Ruth Y. Eberhardt,1 Hilary C. Martin,1 Caroline F. Wright,3
David R. FitzPatrick,4 Helen V. Firth,1,5 and Matthew E. Hurles1,*SummaryStructural variation (SV) describes a broad class of genetic variation greater than 50 bp in size. SVs can cause a wide range of genetic dis-
eases and are prevalent in rare developmental disorders (DDs). Individuals presenting with DDs are often referred for diagnostic testing
with chromosomal microarrays (CMAs) to identify large copy-number variants (CNVs) and/or with single-gene, gene-panel, or exome
sequencing (ES) to identify single-nucleotide variants, small insertions/deletions, and CNVs. However, individuals with pathogenic SVs
undetectable by conventional analysis often remain undiagnosed. Consequently, we have developed the tool InDelible, which interro-
gates short-read sequencing data for split-read clusters characteristic of SV breakpoints. We applied InDelible to 13,438 probands with
severe DDs recruited as part of the Deciphering Developmental Disorders (DDD) study and discovered 63 rare, damaging variants in
genes previously associated with DDs missed by standard SNV, indel, or CNV discovery approaches. Clinical review of these 63 variants
determined that about half (30/63) were plausibly pathogenic. InDelible was particularly effective at ascertaining variants between 21
and 500 bp in size and increased the total number of potentially pathogenic variants identified by DDD in this size range by 42.9%. Of
particular interest were seven confirmed de novo variants in MECP2, which represent 35.0% of all de novo protein-truncating variants in
MECP2 among DDD study participants. InDelible provides a framework for the discovery of pathogenic SVs that are most likely missed
by standard analytical workflows and has the potential to improve the diagnostic yield of ES across a broad range of genetic diseases.Structural variation (SV) includes a diverse collection of
genomic rearrangements such as copy number variation
(CNV), mobile element insertions (MEIs), inversions,
translocations, and others.1 Depending on population
ancestry and technology used, the typical human genome
harbors between 7,000 and 25,000 polymorphic SVs, with
the majority constituting bi-allelic CNVs andMEIs.2 While
most SVs have minimal, if any, functional impact, SVs
have been recognized as causative variants in congenital
disorders.3–5
In diagnostic testing of suspected genetic disorders, SVs
are often identified using chromosomal microarrays
(CMAs) which offer a low-cost albeit low-resolution
method for the identification of large CNVs (typically
>20 kbp in length for genic regions). CMAs are still widely
used by diagnostic laboratories despite the increasing
maturity of genome sequencing-based tools for SV discov-
ery6 and the wealth of clinically ascertained exome-
sequencing (ES) data already generated for the ascertain-
ment of single-nucleotide variants (SNVs) and small
insertions/deletions (indels).7 There are several reasons
for this. First, the cost, computational power, and infor-
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healthcare providers.8 Second, current ES-based SV-discov-
ery approaches focus on methods that interrogate
sequencing coverage to identify regions of copy number
variation within one genome compared to others.9 As
such, ascertainment is typically limited to CNVs of size
>10 kbp, with resolution largely a factor of the sequencing
depth and the density and number of baits in the ES assay,
analogous to probes in CMAs. Thus, despite potentially of-
fering improvements in CNVascertainment over CMAs, ES
as a tool for the assessment of diagnostic SVs has been slow
to enter the clinic.10
Consequently, individuals with genetic abnormalities
smaller than the discovery resolution of CMA or standard
SV-ES approaches (>10 kbp) but larger than variants able
to be accurately called using typical SNV/indel-based ap-
proaches (<50 bp)11 often remain undetected, here termed
‘‘cryptic.’’ To address this unmet need, we have developed
the tool InDelible, which examines ES data for split read
pairs indicative of SV breakpoints. We decided to focus
on split reads because the formation of unique junction se-
quences is a shared characteristic of a broad range of
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Figure 1. InDelible SV discovery in ES
data
InDelible processes one ES sample pro-
vided in BAM or CRAM format via six pri-
mary steps (tan boxes). First, alignment
files are queried for all reads where part of
the aligned sequence matches the refer-
ence genome and the other does not (i.e.,
split reads; Fetch). Next, reads are clustered
(Aggregate) and scored using a random for-
est model15 trained using a variant truth
set (Score; see Figure S1 and supplemental
material and methods for more detail).
Split reads are then merged within clusters
across individuals to determine the longest
quality junction sequence and mapped
back to the genome with bwa mem16 and
to a set of curated repeats with blastn.17
These alignments are then used to
determine breakpoint frequency, likely breakpoints, length, and structural variant class (i.e., deletion, duplication, insertion, etc.; Data-
base). Split read clusters are subsequently annotated with population frequency and intersection with genomic functional annotations,
such as protein-coding genes (Annotate). Finally, clusters are assessed for presence or absence in parental samples, where available, to
determine inheritance status and identify likely de novo variants (denovo). All of these commands can be run on one sample via the
‘‘Complete’’ command (blue box). InDelible also includes the ‘‘Train’’ command to train a new random forest model from user-provided
labeled training data.generated from 13,438 probands with severe develop-
mental disorders (DDs) recruited as part of the Deciphering
Developmental Disorders (DDD) study. Approximately
29% of DDD probands harbor a pathogenic de novo muta-
tion in a gene known to be associated with DD7 and have
been previously assessed for a wide range of variant classes
such as coding,7 noncoding,12 and splice site13 SNVs and
indels, multinucleotide variants,14 mobile element inser-
tions,3 and copy number variants (unpublished data). As
such, the DDD study represents an ideal opportunity to
demonstrate the additive diagnostic potential of identifica-
tion of SVs at scale using split-read information.
InDelible variant discovery and analysis proceeds in
several steps (Figure 1; detailed description in supple-
mental material and methods). In summary, InDelible
identifies split reads, aggregates them into clusters at the
same genomic location, filters these clusters to remove
technical artifacts and retain likely genetic variants, and
then combines unaligned portions of split reads and
maps them to the genome to characterize the nature of
the variant. InDelible also calculates the frequency of
each split-read cluster across a population of individuals
to facilitate the filtering of variants on the basis of minor
allele frequency.
InDelible is coded in Python, uses the pysam (see web re-
sources) library for sequence alignment file manipulation
(Table S1), and works on bwa-aligned BAM or CRAM
format files.18 We have designed InDelible to be scalable
for datasets comprising individual probands tomulti-thou-
sand sample cohorts and our estimates suggest that, to
analyze a dataset of 1,000 trios, InDelible would require
approximately 1556 CPU h, or 15.6 h of real time on a
100-core compute cluster (Figure S2). Additionally, for
easy implementation on cloud compute platforms, we
have made InDelible available as a Docker image (seeThe American Joursupplemental material and methods and data and code
availability).
We benchmarked InDelible against GATK11 and
Manta,19 another SV detector which utilizes split reads,
for variants across a range of allele frequencies and sizes.
First, we ran these callers on ES data generated for a control
individual by the Genome in a Bottle Consortium.20,21 We
then used the gold-standard variant dataset provided by
the Genome in a Bottle Consortium for the same individ-
ual, which amalgamates variant-call data across several
data types including whole genome short-, linked-, and
long-read sequencing, to assess recall and specificity of
the resulting ES calls for each algorithm (Figure S3;
supplemental material and methods). When using ES
data, InDelible equals or exceeds the recall of both GATK
and Manta for variants between 21 and 10 kbp in length,
the variant space InDelible was targeted to identify. Rela-
tive to InDelible, GATK and Manta had 81.7% and 15.0%
recall for deletions >20 bp in length, respectively, and
86.9% and 8.2% recall for insertions >20 bp in length,
respectively. In this same experiment InDelible has moder-
ately increased false discovery rates compared to GATK
(Figure S3). These issues can likely be attributed to
InDelible being designed for maximum sensitivity in clin-
ical sequencing data and can likely be abrogated via the
design of better hard filters when analyzing population-
level variants and/or retraining the random forest using
training data from population-level datasets.
A key objective for the design of InDelible was to identify
de novo variants potentially causative of a proband’s disor-
der. As such, variants are primarily filtered on: (1) the
population frequency of the split read cluster to remove
variants too common to be plausibly causative of a rare dis-
order, (2) absence in unaffected parents (when available),
and (3) intersection of variant breakpoints with the codingnal of Human Genetics 108, 2186–2194, November 4, 2021 2187
sequences of known-disease-associated genes. Defining the
precise molecular structure of SVs from short read
sequencing data can be challenging, and evenminor errors
in breakpoint precision can have large consequences on
interpretation (e.g., in- versus out-of-frame indels). Hence,
we opted to identify all variants which intersect relevant
DD-associated genes for further manual curation rather
than relying on generic variant interpretation tools.
To evaluate the utility of InDelible for diagnostic ana-
lyses, we applied InDelible to identify putatively diagnostic
variants in 13,438 probands recruited to the DDD study.
Probands were exome sequenced either with both parents
(trios, n ¼ 9,848) or with one or both parents absent (non-
trios, n ¼ 3,590). We first identified split reads and split
read clusters (Figure 1) to ascertain 353,313,108 redundant
split read clusters across all probands. Random forest
filtering resulted in retention of 30,667,420 high-quality,
redundant split read clusters across all probands, or 8.7%
of originally ascertained loci (supplemental material and
methods, Figure S4). After cluster filtering, we merged all
retained clusters into a set of 1,954,642 non-redundant
split read clusters across all 13,438 probands, with
1,342,050 (68.7%) clusters found only in one proband
(Figure S5). Clusters were evenly distributed across all chro-
mosomes as a function of chromosome length (r2 ¼ 0.739;
Figure S6). Retained clusters were then annotated with pu-
tative breakpoints, intersecting gene(s), and population
frequency. InDelible was also able to determine the
missing 50 or 30 breakpoint, variant length, and variant
type (i.e., deletion, duplication, MEI, etc.) of 199,932
(10.2%) clusters (supplemental material and methods).
Of the clusters which InDelible was able to resolve to a spe-
cific variant type, 65.7% were simple deletions/duplica-
tions, with the remainder comprising complex events,
MEIs, translocations/segmental duplications, and non-
templated insertions (Figure S7). Ascertainment of variant
type and length are dependent on sequencing depth and
population frequency (Figure S5) but are optimized for
the length of variants InDelible is best suited to identify
(20–500 bp; Figure S8). This specificity is best demon-
strated when restricting to clusters that are plausibly
associated with DDD study participant phenotype (see
below); InDelible accurately resolves both breakpoints,
length, and variant type for 86.3% (126/146) of such clus-
ters (Table S2).
We next restricted our variant set to rare (call frequency
< 0.04%) clusters found only in or near (here defined as
within 510 bp of any exon) the coding sequence of 399
dominant or X-linked DD-associated genes from the
Developmental Disorders Genotype-to-Phenotype data-
base (DDG2P).22 Variants identified within individuals
sequenced as a parent-offspring trio were then also as-
sessed for de novo status. Filtering on allele frequency, in-
heritance, and gene intersection resulted in a preliminary
set of 260 candidate indels and SVs across all 13,438 pro-
bands (Figure 2A; Table S2; supplemental material and
methods). Based onmanual variant inspection,23 we deter-2188 The American Journal of Human Genetics 108, 2186–2194, Novmined that 2/260 (0.8%) were erroneously annotated to
have intersected a mono-allelic DD gene, 17/260 (6.5%)
candidate de novo events were likely to be present in a
parent (i.e., parental false negatives), and 23/260 (8.8%)
were unlikely to be real variants (i.e., offspring false posi-
tives). Four probands contributed 52.2% of false positive
variants, indicating that sample selection and/or addi-
tional sample-level QC could further lower the false posi-
tive rate of InDelible (Figure 2A; Table S2).
Following variant quality control, we further curated
variants for those likely to be associated with a proband
phenotype (Figure 2A). We considered variants with a
non-Finnish European minor allele frequency of R1 3
104 (19/260; 7.3%) in the Genome Aggregation Database
(gnomAD)1,24 or presence in other unrelated individuals
within DDD (20/260; 7.7%) as unlikely to be the cause of
the child’s disorder. Additionally, variants confined to in-
trons or 50/30 UTRs were also defined as variants of uncer-
tain significance and were not considered further (33/
260; 12.7%). This final round of filtering left 146 SVs and
large indels which could plausibly explain a proband
phenotype (56 from probands sequenced as trios, 90
from non-trio probands).
We next sought to determine the sensitivity of InDelible
to clinically relevant variants ascertained using alternative
methods. DDD has already identified (across both trio and
non-trio probands) 1,853 rare, plausibly pathogenic vari-
ants with a net size difference R1 bp (i.e., non-SNVs) in
the same DDG2P gene set defined above7—variants poten-
tially detectable with a split read-based method such as that
employed by InDelible. The majority of these variants are
private or low-allele frequency small indels between 1 and
10 bp in size (1,218/1,853; 65.7%) or large CMA or ES-ascer-
tained CNVs R10 kbp in length (410/1,853; 22.1%;
Figure 2B). As anticipated due to the low number of split
reads at variant breakpoints as variant size decreases,
InDelible performed poorly in identification of very short
variants %10 bp with an overall sensitivity of 1.4%
(Figure 2C). Sensitivity improved as a function of variant
size, peaking at 48.3% sensitivity for variants between 21
and 50 bp, but dropped again for variantsR100 bp. To bet-
ter understand why InDelible missed such variants, we
manually curated the 34 potentially pathogenic variants be-
tween 21 and 500 bp not identified by InDelible. We found
that InDelible missed variants for three primary reasons.
First, these potentially pathogenic variants include some
higher-frequency variants that are too common to be plau-
sibly pathogenic whose true allele frequency was underesti-
mated previously, but have now been more accurately
determined by InDelible and thus subsequently filtered
out (n ¼ 12/34; 35.3%). Second, several variants have low
split read support (i.e., <5 reads) despite being located in
high-coverage regions and were thus excluded by our strin-
gent filtering approach (n¼ 11/34; 32.4%). Third, as variant
size increases, it becomesmore likely that the breakpoints of
SVs which impact coding sequence lie outside of ES target
regions (i.e., within intronic and intergenic sequences).ember 4, 2021
Figure 2. SV ascertainment in the DDD
study with InDelible
(A) Breakdown of putative variant conse-
quences for all 260 variants identified in
this study delineated by whether or not
the proband was sequenced with both par-
ents (trio, tan) or not (proband only, dark
green). Light gray and dark gray boxes
represent erroneous variants and variants
unlikely to be associated with a proband
phenotype, respectively.
(B) Total number of DDD variants reported
to referring clinicians via the DECIPHER
platform among DDD probands with a
net size change R1 bp.
(C) Sensitivity of InDelible to DDD vari-
ants reported to referring clinicians via
the DECIPHER platform among various
variant size bins.
(D) Categorization of InDelible-ascer-
tained variants into previously known (or-
ange) versus those novel (brown) to this
study based on size.
(E) Distribution of variants unique to
InDelible throughout the genome. Shown
in the outer plot are the total number of
InDelible variants per gene, with genes
that have multiple previously undetected
variants labeled. Displayed in the inner
plot are the total number of variants for
each SV type identified.Ergo, such variants are refractory to identification with
split reads and likely to be missed by any split-read caller
(n ¼ 6/34; 17.6%). Combined, these three explanations ac-
count for 85.3% of variants between 21 and 500 bp missed
by InDelible. While variants with breakpoints outside of
sequencing baits are invisible to InDelible, additional fine-
tuning of InDelible’s filtering parameters could, in theory,
output variants with lower split read support or variants
with higher allele frequencies.
These 63 previously undetected variants (four of which
were ascertained by an earlier version of InDelible and
included as part of a previous DDD publication25) that
impact known DD-associated genes (Table S2) are
composed primarily of deletions and duplications (50/63;
79.4%) but also includes variants with diverse mutational
mechanisms such as MEIs, complex rearrangements, and
dispersed duplications/translocations (Figure 2E). 25 of
these variants were observed in trio probands, withThe American Journal of Human Genetics 1parental data supporting a de novo
origin for all of these variants. InDel-
ible was particularly effective at iden-
tifying variants between 21 and
500 bp in size (Figure 2D); 30 previ-
ously undetected variants (47.6% of
InDelible-specific variants) lie within
this size range and represent a 42.9%
increase in putatively pathogenic var-
iants 21–500 bp in length among
DDD probands (Figure 2D). We alsoidentified six genes with multiple previously undetected
SVs among unrelated individuals, of which the most recur-
rently affected was MECP2, the causal gene of Rett syn-
drome (Figure 2E).26
From an initial round of clinical review, based on inter-
secting gene(s) and associated phenotypes, we concluded
that nine (14.3%) of these 63 previously undetected vari-
ants were unlikely to explain the referred proband’s
phenotype, and were thus excluded from future analysis
(Table S2). We next attempted PCR validation of the 54 pu-
tatively pathogenic variants (supplemental material and
methods). Of the variants for which conclusive validation
results could be obtained, 23/23 (100%) were confirmed as
true positives, either by the obvious presence of a mutant
band of expected size with gel electrophoresis or by
follow-up capillary sequencing where the gel result was un-
certain (Table S2). For variants for which PCR was possible,
we also confirmed that 10/10 (100%) putative de novo08, 2186–2194, November 4, 2021 2189
Figure 3. Clustered SVs in MECP2 cause
diverse phenotypes
(A) Shown is a cartoon representation of
the gene MECP2, with stop-gained (black
circles) and missense (gray circles) de novo
SNVs identified in DDD trios. Each circle
represents one proband, with recurrent
variants represented by stacks of circles.
Below the MECP2 gene model, we have
shown the seven variants identified by
InDelible as well as the single whole gene
deletion previously identified via CMA
(proband 279220; arrows indicate this
variant extends beyond the scale shown
in the diagram). Sizes adjacent to variants
represent the difference in number of refer-
ence and alternate bases in the indicated
DDD study participant genome. We have
indicated that the variant in DDD study
participant 258223 only incorporates
non-references bases (i.e., an insertion)
with an asterisk. Variants are colored by
their classification in (B). All InDelible-as-
certained variants overlap the same
326 bp region in the last exon of MECP2.
(B) Diverse proband phenotypes among
MECP2 SV carriers. Each proband carrying
a MECP2 SV from (A) is shown on the x
axis, with phenotypes annotated by the
referring clinician shown on the y axis.
Filled black circles represent when a corre-
sponding proband displays the corre-
sponding phenotype. Colored boxes on
the top of the plot represent the diverse
phenotypes we identified following clin-
ical review. The y axis marginal histogram
represents the number of times the corre-
sponding phenotype was observed among
our SV probands.variants identified in trio probands were indeed absent
from both parents.
All 54 plausible pathogenic variants were reported to
referring clinicians and clinically interpreted by two senior
clinical geneticists; 30/54 (55.6%) were classified as patho-
genic or likely pathogenic by both clinical geneticists
(Table S2). Of these variants, those identified in non-trio
probands (n ¼ 31/54 plausibly pathogenic variants) for
which inheritance status is unavailable, were less likely to
be interpreted as being pathogenic (Fisher’s p ¼ 0.006).
This finding is corroborated by the difference in the pro-
portion of in-frame versus out-of-frame deletions and du-
plications %50 bp between trio and non-trio probands;
80.0% of deletions and duplications are in-frame for
non-trios versus 19.0% for trios (Fisher’s p ¼ 1.5 3 106;
Figure S9). This is consistent with population-level obser-
vations: out-of-frame deletions and duplications are typi-
cally under stronger negative selection than in-frame vari-
ants27 and an increased proportion of in-frame variants in
non-trio probands is suggestive of a greater proportion be-
ing benign. The difference is likely attributable to the
absence of parental data leading to the inclusion of rare
benign inherited variants that are unlikely to be filtered
out using population variation data (e.g., gnomAD1,24).2190 The American Journal of Human Genetics 108, 2186–2194, NovOverall, de novo variants identified by InDelible represent
0.7% (18/2592) of all confirmed diagnoses among trio pro-
bands in the DDD study.
InDelible identified a total of seven confirmed de novo
variants R20 bp in length affecting MECP2 (Figures 2E
and 3A), all predicted to be protein truncating. As expected
and in accordance with known sex bias among individuals
with Rett syndrome,28 all variants were ascertained from
female probands. Out of these seven probands, two have
phenotypes that could be described as consistent with
typical Rett syndrome presentation.28 Through in-depth
clinical curation of HPO terms (see supplemental material
and methods), we grouped probands with putative loss-of-
function mutations caused by SVs in MECP2 into four cat-
egories (Figure 3B). Cases identified by InDelible thus
represent the wide variety of diverse clinical presentations
that can result from disruption of the C terminus of
MECP229 and include previously observed MECP2-associ-
ated phenotypes such as early-onset seizures and Angel-
man-like symptoms (Table S3; Figure 3B).30
Interestingly, all five of our MECP2 variants in probands
without typical Rett syndrome presentation overlapped
the same 326 bp region located within the final coding
exon and, aside from a previously ascertained wholeember 4, 2021
gene deletion (proband 279220), do not overlap with puta-
tively pathogenic SNVs identified within the DDD study
(Figure 3A). The SV-specific region corresponds to an area
of low sequence complexity and has been previously ascer-
tained as hyper-mutable by several studies.29,31 The molec-
ular function of this region ofMECP2 is poorly understood
and it is uncertain as to the consequences that our
described variants may have on protein structure beyond
decreasing transcript abundance and/or overall protein
stability.29
The seven de novo MECP2 variants constitute 28.0% (7/
25) of all novel de novo variants identified by InDelible
and 35.0% (7/20) of all confirmed de novo protein-trun-
cating or gene-deleting variants of MECP2 in the DDD
study7 (Figure 3A).
As several publications have shown that rare, inherited
variants are also important in the genetic architecture of
developmental disorders,32 we next sought to examine
whether InDelible could be used to identify such variants.
We repeated our filtering as described above but limited to
variants found in only a single proband with split read sup-
port from either parent (supplemental material and
methods). This approach identified a total of 145 variants
within the coding sequence of mono-allelic DD genes. As
expected based on our analysis of variants in probands
sequenced without their parents (Figure S9), a large propor-
tion of inherited variants we identified were balanced/in-
frame deletions or duplications with uncertain effect on
the target protein (50; 34.5%). Others either primarily over-
lapped noncoding sequence, were found in an individual
with a more likely diagnostic variant, were large duplica-
tions which only partially overlapped the gene of interest,
were already identified based on an alternate breakpoint
as part of our de novo analysis, or were also identified in con-
trol individuals at high enough allele frequencies to be
considered unlikely to be associated with an individual’s
phenotype.1,24 Initial filtering based on these criteria left a
remainder of 17 variants for clinical interpretation.
Of the remaining inherited variants, seven were already
identified via other approaches and reported to referring
clinicians with six considered as likely benign and one as
likely pathogenic. The remaining ten variants were
referred to the same two senior clinician geneticists as for
our de novo analysis detailed above (Table S4). Of these
ten variants, all but one were unlikely to be involved in in-
dividual phenotype. The sole remaining inherited variant,
an out-of-frame deletion in KAT6B, was identified in a pro-
band-mother pair and was deemed a variant of uncertain
consequence upon initial clinical review. Follow-up with
the referring clinician regarding the mother’s phenotype
determined that the mother did not exhibit any features
of the proband’s disorder. As such, this variant was deemed
to be likely benign. Combined, these data show that
InDelible is effective at identifying rare, inherited variants
but that the overall diagnostic yield may be low.
Here we present the development and application of
InDelible, a tool designed for the rapid assessment of ESThe American Jourdata for breakpoints of rare, pathogenic cryptic SVs
involved in single-gene disorders (Figure 1). We applied
InDelible to 13,438 proband genomes sequenced as part
of the DDD study and identified a total of 146 candidate
pathogenic variants impacting genes associated with
dominant or X-linked DD (Figure 2A, Table S2). Of these
146 variants, 63 were not previously identified in DDD
probands, despite the wide range of SVand InDel detection
algorithms that have previously been deployed on this
cohort.7,25 Notably, we increased the number of putatively
diagnostic variants among DDD probands 21–500 bp in
length by 42.9% (Figure 2D). Through conservative clinical
assessment of these 63 variants, we determined that 30
(47.6%) of our previously undetected variants were consid-
ered likely causative of proband phenotype—of particular
interest was the large number of protein-truncating SVs
we identified in MECP2 (Figure 3).
The variant size range which InDelible interrogates is
complementary to other approaches commonly used for
variant discovery from ES data.9,11 While other previously
described algorithms have also attempted to mine split
read information for structural variant detection,11,19,33
they have different properties that preclude meaningful
comparison with InDelible.11 Some have been trained
primarily on genome sequencing data rather than ES
data,19,33 others do not explicitly assess de novo status,
and many are not readily scalable to a dataset of 10,000
trios. As such, we have built InDelible to be scalable to
many thousands of samples (Figure S2).
Other studies have previously noted that 10% of all
MECP2 variants in probands ascertained based on presen-
tation of Rett-associated phenotypes were deletions31,34
and a large number of pathogenic or likely pathogenic var-
iants in ClinVar fall within the same region of MECP2 that
we detail in this manuscript. These observations, com-
bined with the diverse phenotypes that this study has
identified (Figure 3B), further complicate the clinical inter-
pretation of variants disrupting MECP2. In particular, the
work of Guy et al.29 found that slight differences between
the size and sequence context of deletions in the C-termi-
nal domain ofMECP2 can have significant ramifications in
RNA/protein expression. Additionally, Huppke et al.35
found that skewed X-inactivation could play a role in the
severity of MECP2 presentation. Further work is needed
to understand how different classes of mutation lead to
diverse phenotypes in individuals with MECP2 loss-of-
function variants. However, most importantly and exem-
plifying the additive power of InDelible, if not applied to
the DDD study, 20.6% of DDD probands with clinically
relevant MECP2 variants would not have received a diag-
nosis for their disorder.
InDelible was designed to detect variant breakpoints
missed by other approaches in ES data from individuals
with DDs. This has three major ramifications for the design
of InDelible and the variants discussed as part of this study.
First, as the primary cause of DDs is highly penetrant domi-
nant de novo variants,7 InDelible variant discovery wasnal of Human Genetics 108, 2186–2194, November 4, 2021 2191
Figure 4. Added diagnostic PTV yield of
InDelible
Total number of de novo PTVs (y axis) ascer-
tained in DD-associated genes when using
InDelible alone, or in combination with a
subset of three additional algorithms
(GATK,11 XHMM,9 or MELT3,36). Percent-
ages represent the proportion of all PTVs
specific to InDelible (green text) or
XHMM (orange text) for each bar. The red
line and axis label indicates the maximum
number of de novo PTVs identified in DD-
associated genes among 9,848 DDD trio
probands if combining data from all four
algorithms (n ¼ 1,285 variants).focused on identifying such variants from a defined list of
genes known to be associated with DDs.22 As briefly
demonstrated above for rare inherited variation, this does
not preclude the use of InDelible to identify variants acting
through other modes of inheritance; InDelible will iden-
tify variants across the entire allele frequency spectrum
and outside of the provided gene list as part of the primary
output.
Second, theDDDcohorthasbeenpreviously investigated
for a broader range of variant classes (using both different
assays and algorithms) than most ES studies. For ES-based
CNVdiscovery from read-depth,DDDapplied four separate
algorithms to build a joint call set (unpublished data). Thus,
the added diagnostic value of running InDelible is probably
under-estimated in the DDD study compared to other ES
studies and/or common clinical sequencing practices
whichwouldbeunlikely to utilize complex joint-calling ap-
proaches such as our own. To quantify the added diagnostic
value of running InDelible across different settings by a user
seeking to run a minimal number of algorithms, we esti-
mated the proportion of unique PTVs InDelible would
find if used alone or jointly with other algorithms targeting
a breadthof variant types (SNVs, indels, large deletions, and
MEIs; supplemental material and methods).3,9,11 Overall,
and when using other approaches, InDelible-specific vari-
ants will likely represent between 2%–3% of all PTVs in a
given cohort (Figure 4). This observation strongly implies
that workflows that do not incorporate algorithms capable
of detecting this class of cryptic variation are likely to
achieve only 97%–98% sensitivity for pathogenic PTVs.
Finally, we note that InDelible is unlikely to be more
effective than currently available tools when applied to
genome-sequencing data. In ES, discordant read pairs are
typically much less informative for detecting SVs than in
genome sequencing due to the inherent properties of the
data. In genome sequencing, data combining split and
discordant read-pair information is a better means to iden-
tify most SV types.
InDelible provides a rapid framework for the assessment
of ES data for intermediate-length pathogenic SVs of
diverse mutational origins. Our results show that through
a combination of enhanced algorithm design, variant
annotation, and clinical interpretation, ongoing interroga-2192 The American Journal of Human Genetics 108, 2186–2194, Novtion of well-studied datasets will continue to yield
improved diagnoses.Data and code availability
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